JP2014520090A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520090A5
JP2014520090A5 JP2014511911A JP2014511911A JP2014520090A5 JP 2014520090 A5 JP2014520090 A5 JP 2014520090A5 JP 2014511911 A JP2014511911 A JP 2014511911A JP 2014511911 A JP2014511911 A JP 2014511911A JP 2014520090 A5 JP2014520090 A5 JP 2014520090A5
Authority
JP
Japan
Prior art keywords
weight
component
preferred range
diacylglycerol
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511911A
Other languages
English (en)
Japanese (ja)
Other versions
JP6265888B2 (ja
JP2014520090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/059917 external-priority patent/WO2012160213A1/en
Publication of JP2014520090A publication Critical patent/JP2014520090A/ja
Publication of JP2014520090A5 publication Critical patent/JP2014520090A5/ja
Application granted granted Critical
Publication of JP6265888B2 publication Critical patent/JP6265888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511911A 2011-05-25 2012-05-25 制御放出ペプチド製剤 Active JP6265888B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25
US61/489,886 2011-05-25
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017228735A Division JP6415673B2 (ja) 2011-05-25 2017-11-29 制御放出ペプチド製剤

Publications (3)

Publication Number Publication Date
JP2014520090A JP2014520090A (ja) 2014-08-21
JP2014520090A5 true JP2014520090A5 (enExample) 2018-01-18
JP6265888B2 JP6265888B2 (ja) 2018-01-24

Family

ID=46456496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014511911A Active JP6265888B2 (ja) 2011-05-25 2012-05-25 制御放出ペプチド製剤
JP2017228735A Active JP6415673B2 (ja) 2011-05-25 2017-11-29 制御放出ペプチド製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017228735A Active JP6415673B2 (ja) 2011-05-25 2017-11-29 制御放出ペプチド製剤

Country Status (37)

Country Link
US (3) US11433120B2 (enExample)
EP (2) EP2714004B1 (enExample)
JP (2) JP6265888B2 (enExample)
KR (1) KR102066755B1 (enExample)
CN (2) CN103702662B (enExample)
AR (1) AR086577A1 (enExample)
AU (2) AU2012260821B2 (enExample)
BR (1) BR112013030104A8 (enExample)
CA (1) CA2836847C (enExample)
CL (1) CL2013003365A1 (enExample)
CO (1) CO6900117A2 (enExample)
CR (1) CR20130653A (enExample)
CU (1) CU20130158A7 (enExample)
DK (1) DK2714004T3 (enExample)
DO (1) DOP2013000275A (enExample)
EA (1) EA036213B1 (enExample)
EC (1) ECSP13013107A (enExample)
ES (1) ES2984717T3 (enExample)
FI (1) FI2714004T3 (enExample)
GT (1) GT201300292A (enExample)
HR (1) HRP20240781T1 (enExample)
HU (1) HUE067389T2 (enExample)
IL (1) IL229376B (enExample)
LT (1) LT2714004T (enExample)
MX (1) MX361716B (enExample)
MY (1) MY177820A (enExample)
NI (1) NI201300127A (enExample)
PE (1) PE20141484A1 (enExample)
PH (1) PH12013502550A1 (enExample)
PL (1) PL2714004T3 (enExample)
PT (1) PT2714004T (enExample)
RS (1) RS65702B1 (enExample)
SG (1) SG194865A1 (enExample)
SI (1) SI2714004T1 (enExample)
TW (1) TWI624271B (enExample)
WO (1) WO2012160213A1 (enExample)
ZA (1) ZA201309653B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
ES2731524T3 (es) 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
EP3045162B1 (en) 2012-07-26 2021-07-07 Camurus AB Opioid formulations
SG11201500554XA (en) 2012-07-26 2015-02-27 Camurus Ab Opioid formulations
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
WO2018050864A1 (en) 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
EP3710041A4 (en) * 2017-11-15 2021-08-18 Rhythm Pharmaceuticals, Inc. DELAYED RELEASE PEPTIDE FORMULATIONS
MX2020009150A (es) 2018-03-02 2020-12-11 Elicio Therapeutics Inc Anfifilos de cpg y usos de los mismos.
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
MX2021014450A (es) 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
IL308133A (en) * 2021-05-04 2023-12-01 Camurus Ab Compositions and methods for treating neuroendocrine tumors
WO2024263085A1 (en) * 2023-06-20 2024-12-26 Camurus Ab Compositions and methods for treating acromegaly
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682091B1 (en) * 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
AU2005324794C1 (en) 2003-11-07 2010-12-02 Camurus Ab Somatostatin analogue formulations
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
GB0417388D0 (en) 2004-08-04 2004-09-08 Camurus Ab Composition
EP1778187B1 (en) 2004-08-04 2012-05-23 Camurus Ab Compositions forming non-lamellar dispersions
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
BR112014013693B1 (pt) * 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt

Similar Documents

Publication Publication Date Title
JP2014520090A5 (enExample)
JP2014102408A5 (enExample)
JP2012520430A5 (enExample)
JP2013514381A5 (enExample)
JP2015512729A5 (enExample)
JP2010219032A5 (enExample)
JP2013500200A5 (enExample)
JP2014517802A5 (enExample)
JP2014138100A5 (enExample)
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
JP2012081521A5 (enExample)
JP2013510216A5 (enExample)
JP2015522045A5 (enExample)
JP2011177279A5 (enExample)
JP2012502876A5 (enExample)
JP2015520964A5 (enExample)
JP2015518492A5 (enExample)
JP2013508091A5 (enExample)
JP2012094862A5 (enExample)
JP2014500291A5 (enExample)
JP2012049345A5 (enExample)
JP2011242375A5 (enExample)
JP2013005790A5 (enExample)
JP2013531183A5 (enExample)
JP2009055850A5 (enExample)